[HTML][HTML] Efficacy and toxicity of carfilzomib-or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A …
C Xie, M Wei, F Yang, Q Liu, F Wu, J Huang - Medicine, 2022 - journals.lww.com
Background: Multiple myeloma is a clonal disorder of malignant plasma cells that comprises
approximately 10% of hematologic malignancies. The aim of this study was to investigate …
approximately 10% of hematologic malignancies. The aim of this study was to investigate …
[HTML][HTML] Efficacy and toxicity of carfilzomib-or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A …
C Xie, M Wei, F Yang, Q Liu, F Wu, J Huang - Medicine, 2022 - ncbi.nlm.nih.gov
Background: Multiple myeloma is a clonal disorder of malignant plasma cells that comprises
approximately 10% of hematologic malignancies. The aim of this study was to investigate …
approximately 10% of hematologic malignancies. The aim of this study was to investigate …
[HTML][HTML] Efficacy and toxicity of carfilzomib-or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A …
C Xie, M Wei, F Yang, Q Liu, F Wu, J Huang - Medicine, 2022 - journals.lww.com
Background: Multiple myeloma is a clonal disorder of malignant plasma cells that comprises
approximately 10% of hematologic malignancies. The aim of this study was to investigate …
approximately 10% of hematologic malignancies. The aim of this study was to investigate …
Efficacy and toxicity of carfilzomib-or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A meta …
C Xie, M Wei, F Yang, Q Liu, F Wu, J Huang - Medicine, 2022 - pubmed.ncbi.nlm.nih.gov
Background Multiple myeloma is a clonal disorder of malignant plasma cells that comprises
approximately 10% of hematologic malignancies. The aim of this study was to investigate …
approximately 10% of hematologic malignancies. The aim of this study was to investigate …
Efficacy and toxicity of carfilzomib-or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A meta …
C Xie, M Wei, F Yang, Q Liu, F Wu, J Huang - Medicine, 2022 - europepmc.org
Background Multiple myeloma is a clonal disorder of malignant plasma cells that comprises
approximately 10% of hematologic malignancies. The aim of this study was to investigate …
approximately 10% of hematologic malignancies. The aim of this study was to investigate …
Efficacy and toxicity of carfilzomib-or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A meta …
C Xie, M Wei, F Yang, Q Liu, F Wu, J Huang - Medicine, 2022 - europepmc.org
Background Multiple myeloma is a clonal disorder of malignant plasma cells that comprises
approximately 10% of hematologic malignancies. The aim of this study was to investigate …
approximately 10% of hematologic malignancies. The aim of this study was to investigate …